Labcorp Holdings Inc. is a global life sciences and healthcare company providing comprehensive laboratory services. The company operates through two primary business segments: Diagnostics (Dx), which offers routine and specialty clinical testing, and Biopharma Laboratory Services (BLS), which includes Central Laboratory and Environmental, Disposition, and Safety (ED) businesses. Key services include core patient testing, specialty testing in oncology, women’s health, autoimmune disease, and neurology, as well as drug development support and cell and gene therapy laboratory capabilities. The company serves a broad range of customers, including physicians, hospitals, health systems, health plans, Medicare and Medicaid participants, patients, and pharmaceutical, biotechnology, and medical device companies. Its operations span North America, Europe, and other international regions, with a significant presence in the U.S. and Canada. Notable initiatives include the Labcorp OnDemand channel for direct-to-consumer testing and a minority stake acquisition in SYNLAB to expand its European footprint. The company also supports clinical trials and companion diagnostic development for biopharma partners.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage labcorp.com
Sector Healthcare IR page labcorp.com/biopharma/commercialization/investors
Tags
clinical laboratory testing, specialty diagnostics, biopharma laboratory services, central laboratory, companion diagnostics, cell and gene therapy, oncology testing, women's health testing, autoimmune disease testing, neurology testing, drug development support, direct-to-consumer testing, Labcorp OnDemand, SYNLAB
Press page labcorp.com/newsroom

Metrics

Valuation  
Market cap $ 30.253B
Market cap (USD) $ 30.253B
P/E 30.56
PEG —
P/BV 3.42
P/S 2.07
P/OCF 16.67
P/FCF 23.51
Dividend yield <0.01%
Turnover / mcap —
Returns  
ROE 10.5%
ROI 6.2%
ROIC 7.7%
Profit margin 6.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -11.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 66.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 73
Quality score 5.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2006 FY 2005 FY 2002 FY 2001 FY 2000
Revenue 13.952B 13.009B 12.162B 14.877B 16.121B 13.979B 11.555B 11.333B 10.441B 9.642B 8.68B 6.012B 5.808B 5.671B 5.542B 5.004B 4.695B 4.505B 3.591B 3.328B 2.508B 2.2B 1.919B
Net profit 876.5M 746M 418M 1.279B 2.377B 1.556B 823.8M 883.7M 1.268B 732.1M 436.9M 511.2M 573.8M 583.1M 519.7M 558.2M 543.3M 464.5M 431.6M 386.2M 254.6M 179.5M 77.5M
Free cash flow 1.206B 1.096B 874.1M 1.474B 2.649B 1.754B 1.045B 925.6M 1.147B 897M 726.6M 535.5M 616.5M 667.6M 709.9M 757.5M 747.7M 624.2M 516.4M 480.6M — — 191.2M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2006 FY 2005 FY 2002 FY 2001 FY 2000
Share price 250.88 229.32 227.29 235.47 302.28 214.59 165.23 162.14 153.52 140 123.31 105.11 90.79 89.74 88 87.95 74 62.26 73.77 55 — — —
Price performance 12m 0.09 0.01 -0.03 -0.22 0.41 0.3 0.02 0.06 0.1 0.14 0.17 0.16 0.01 0.02 0 0.19 0.19 -0.13 0.34 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.33B 1.48B 1.47B 1.54B 2.48B 2.26B 2.22B 1.91B 1.94B 2.1B
↳ YoY growth +9.1% +11.5% -0.9% +5.2% +60.6% -8.8% -1.7% -13.9% +1.6% +8.2%
↳ 5y CAGR +13.7% +15.6% +13.3% +13.6% +15.3% +11.2% +8.4% +5.4% +4.7% -3.2%
Borrowings, current (USD) 541M 409M 10M 415M 377M 1.5M 301M 1,000M 1B 500M
Borrowings, non-current (USD) 5.3B 6.34B 6.04B 5.79B 5.42B 5.42B 5.04B 4.05B 5.33B 5.08B
Lease liabilities (USD) — — 58.9M 903M 91.1M 925M 955M 900M 941M 941M
Cash and deposits (USD) 434M 317M 427M 338M 1.32B 1.47B 430M 537M 1.52B 532M
Intangible assets (USD) 3.4B 4.34B 3.91B 4.03B 3.96B 3.74B 3.95B 3.34B 3.49B 3.6B
Right-of-use assets (USD) — — — 733M 790M 746M 774M 737M 785M 804M
Net debt (borrowings + leases - cash) (USD) 5.41B 6.44B 5.63B 6.77B 4.57B 4.87B 5.86B 5.42B 5.75B 5.99B
Cash flow detail
Operating cash flow (USD) 1.18B 1.46B 1.31B 1.44B 2.14B 3.11B 1.96B 1.33B 1.59B 1.64B
Purchases of property, plant and equipment (USD) -279M -313M -380M -400M -382M -460M -482M -454M -490M -435M
Purchases of intangible assets (USD) 0.00 -2.5M 0.00 0.00 — — — — — —
Change in receivables (cash effect) (USD) -85.5M -2.1M 50.2M -64.1M -913M 222M 15.9M -104M -52.3M -126M
Change in inventories (cash effect) (USD) -9.6M -16.4M -18.9M -21.9M -197M 2.8M -45.5M -700,000 -12.6M -30.2M
Change in payables (cash effect) (USD) -8.7M 85.6M 43.3M -12.8M -5.3M -10.2M 307M -42.4M 72.1M -52.8M
Dividends paid (cash effect) (USD) — — — — — — -195M -254M -243M -241M
Share buybacks (cash effect) (USD) -43.9M -338M -700M -450M -100M -1.67B -1.1B -1B -250M -450M
Income taxes paid (cash effect) (USD) -346M -348M -350M -217M -500M -1B -505M -207M -215M -171M
Share-based compensation (USD) 110M 110M 91.6M 107M 112M 154M 144M 129M 117M 126M
Operating cash flow before change in receivables (USD) 1.26B 1.46B 1.26B 1.51B 3.05B 2.89B 1.94B 1.43B 1.64B 1.77B
Free cash flow (OCF - PPE - intangibles) (USD) 897M 1.14B 926M 1.04B 1.75B 2.65B 1.47B 874M 1.1B 1.21B
Income detail
Total comprehensive income (USD) 439M 1.52B 755M 916M 1.77B 2.35B 979M 615M 545M 1.11B
Comprehensive income to owners (USD) 438M 1.51B 754M 915M 1.77B 2.35B 978M 614M 544M 1.11B
Provision for credit losses (USD) 287M 315M — — 7M 3.8M 15.1M 6.3M 14.6M 4.3M
Credit cost ratio (credit losses / average receivables) (%) 22.6% 22.4% — — 0.3% 0.2% 0.7% 0.3% 0.8% 0.2%
Reported Feb 27, 2018 Feb 27, 2018 May 3, 2019 Feb 28, 2020 Feb 25, 2021 Feb 25, 2022 Feb 25, 2025 Feb 25, 2025 Feb 25, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Racquel White Nickolo Russo Bull 0 Bear 0 Routine

[email protected] [email protected]

Labcorp to Speak at the UBS Global Healthcare Conference

BURLINGTON, N.C., (Nov. 4, 2026) — Labcorp Holdings, Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10 at 8:45 a.m. ET.

A live audio webcast of the fireside chat will be available via the Labcorp Investor Relations website at ir.Labcorp.com and archived for 180 days following the event.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world.

Labcorp Logo

Your Opt Out Preference Signal is Honored

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

If you wish to exercise your right to opt out of the sale or sharing of your personal information for targeting advertising, please disable “Targeting Cookies”.

Accept All Cookies

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Optimize Website Experience

Optimize Website Experience

The 'Optimize Website Experience' setting enhances your interaction with Labcorp’s sites by enabling both functional and performance cookies. By toggling this option on, it allows us to tailor the website to your preferences and improve its overall efficiency. Functional cookies remember your choices, such as language settings or login details, ensuring a more personalized and seamless experience. Performance cookies, on the other hand, collect anonymous data on how you use the site, helping us identify areas for improvement and optimize the website's speed and responsiveness. Together, these cookies work to provide you with a smoother, more engaging online experience.

  • Functional Cookies

Switch Label

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

  • Performance Cookies

Switch Label

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All Non-Essential Cookies

Powered by Onetrust

Acquisition aims to expand toxicology testing access nationwide and provide clinical insights to support patients living with chronic pain, substance use disorders and mental health challenges

BURLINGTON, N.C., Nov. 4, 2026 – Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announces it has completed its acquisition of Millennium Health, an accredited specialty laboratory with more than 15 years of experience in drug testing and surveillance.

Millennium Health provides critical insights into patients’ recent use of prescription medications and/or illicit drugs, helping clinicians more effectively monitor and treat individuals living with chronic pain, substance use disorders, mental health conditions and other health needs.

“The completion of this acquisition marks an important step in strengthening Labcorp’s toxicology capabilities and expanding access to these important testing services for patients across the country,” said Andrea Throop, Ph.D., Head of Toxicology at Labcorp. “By bringing together Labcorp’s national scale, scientific expertise and digital capabilities with Millennium Health’s deep experience in toxicology testing and drug surveillance, we are well positioned to support healthcare providers with actionable information that helps improve patient care and outcomes.”

Upon integration, patients, clinicians and Millennium customers are expected to benefit from Labcorp’s extensive test menu, patient service center (PSC) network of convenient locations across the U.S. and leading digital solutions to assist with test ordering and result delivery.

Hogan Lovells Cadwalader served as legal counsel for Labcorp, and Blank Rome served as legal counsel for Millennium Health.

About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements with respect to the anticipated benefits to physicians, patients and customers of the transaction between Millennium Health and Labcorp, including broader access to toxicology services, Labcorp’s extensive test menu and patient service center network and digital solutions to support test ordering and result delivery, as well as how the transaction will further support Labcorp's business strategies.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond Labcorp's control. These factors, in some cases, have affected and in the future (together with other factors) could affect Labcorp's ability to implement its business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in Labcorp's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in subsequent quarterly reports on Form 10-Q and its other filings with the SEC. The information in this press release should be read in conjunction with a review of Labcorp's filings with the SEC including the information in its most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".

Media Racquel White [email protected]

Investors Nickolo Russo [email protected]

Labcorp Logo

Your Opt Out Preference Signal is Honored

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

If you wish to exercise your right to opt out of the sale or sharing of your personal information for targeting advertising, please disable “Targeting Cookies”.

Accept All Cookies

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Optimize Website Experience

Optimize Website Experience

The 'Optimize Website Experience' setting enhances your interaction with Labcorp’s sites by enabling both functional and performance cookies. By toggling this option on, it allows us to tailor the website to your preferences and improve its overall efficiency. Functional cookies remember your choices, such as language settings or login details, ensuring a more personalized and seamless experience. Performance cookies, on the other hand, collect anonymous data on how you use the site, helping us identify areas for improvement and optimize the website's speed and responsiveness. Together, these cookies work to provide you with a smoother, more engaging online experience.

  • Functional Cookies

Switch Label

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

  • Performance Cookies

Switch Label

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All Non-Essential Cookies

Powered by Onetrust

Prompts

Labcorp Holdings Inc. (ticker LH), listed in United States.

Company History

Date Change Detail
May 17, 2024 Renamed LABORATORY CORP OF AMERICA HOLDINGS → LABCORP HOLDINGS INC.

ETFs Holding Labcorp Holdings Inc.

ETF Weight in ETF Shares Market value As of
DHLX 4.81% 14,961 $ 4.189M Jun 30, 2026
ASLV 3.25% 23,004 $ 7.113M Jul 31, 2026
KNO 2.19% 3,556 $ 995.68K Jun 30, 2026
CVRD 2.19% 2,500 $ 700K Jun 30, 2026
CAMX 2.17% 4,775 $ 1.476M Jul 31, 2026
EPMB 2.00% 249 $ 92.25K Nov 13, 2026
EPMV 2.00% 254 $ 94.102K Nov 13, 2026
SAGP 1.95% 5,338 $ 1.495M Jun 30, 2026
BASV 1.91% 27,872 $ 7.804M Jun 30, 2026
EPSV 1.80% 285 $ 105.587K Nov 13, 2026
BUSA 1.45% 15,499 $ 4.34M Jun 30, 2026
TSME 1.16% 43,523 $ 12.186M Jun 30, 2026
ZECP 0.98% 11,128 $ 3.702M Aug 31, 2026
THMZ 0.92% 1,781 $ 498.68K Jun 30, 2026
ABCS 0.71% 267 $ 88.82K Aug 31, 2026
HUSV 0.71% 1,091 $ 406.354K Nov 16, 2026
ITAN 0.64% 2,157 $ 794.294K Nov 17, 2026
JSTC 0.56% 4,396 $ 1.637M Nov 17, 2026
HWSM 0.55% 54 $ 15.12K Jun 30, 2026
PAPI 0.54% 7,757 $ 2.172M Jun 30, 2026
FBCV 0.49% 2,817 $ 871.016K Jul 31, 2026
ACVU 0.47% 3,515 $ 0.00 Nov 18, 2026
BTAL 0.45% 4,554 $ 1.275M Jun 30, 2026
AVMC 0.32% 4,739 $ 1.765M Nov 16, 2026
PHEQ 0.31% 1,550 $ 434K Jun 30, 2026
INRO 0.30% 4,683 $ 1.744M Nov 16, 2026
DFLV 0.22% 44,472 $ 16.558M Nov 12, 2026
IALT 0.19% 40,769 $ 15.185M Nov 16, 2026
DFUV 0.14% 60,500 $ 22.525M Nov 12, 2026
FTLS short -0.13% -8,718 $ 0.00 Nov 16, 2026
DXUV 0.11% 17,977 $ 6.693M Nov 12, 2026
CAPE 0.11% 905 $ 253.4K Jun 30, 2026
DFAC 0.09% 217,591 $ 81.013M Nov 12, 2026
DCOR 0.08% 102,646 $ 38.217M Nov 12, 2026
AVSU 0.08% 1,056 $ 393.318K Nov 16, 2026
AAUS 0.08% 1,145 $ 420K Nov 18, 2026
DFVX 0.08% 1,177 $ 438.221K Nov 12, 2026
XMAG 0.07% 379 $ 141.109K Nov 13, 2026
DFSU 0.07% 4,398 $ 1.637M Nov 12, 2026
APUE 0.07% 5,051 $ 1.68M Aug 31, 2026
EBI 0.06% 1,297 $ 431.46K Aug 31, 2026
DFAU 0.06% 20,302 $ 7.559M Nov 12, 2026
MODL 0.05% 1,798 $ 503.44K Jun 30, 2026
ACVF 0.05% 228 $ 70.498K Jul 31, 2026
DFUS 0.04% 24,967 $ 9.296M Nov 12, 2026
AVLC 0.04% 1,908 $ 710.654K Nov 16, 2026
GDE 0.04% 523 $ 173.981K Aug 31, 2026
NTSX 0.04% 1,744 $ 488.32K Jun 30, 2026
VOXP 0.03% 6 $ 1,855.20 Jul 31, 2026
HCMT 0.03% 571 $ 176.553K Jul 31, 2026
MSLC 0.03% 3,192 $ 1.062M Aug 31, 2026
AVUS 0.02% 9,729 $ 3.624M Nov 16, 2026
CSHP 0.02% 190 $ 70.767K Nov 16, 2026
GSPY 0.02% 288 $ 107.268K Nov 17, 2026
NTSD 0.02% 21 $ 5,880.00 Jun 30, 2026
VSLU 0.01% 292 $ 81.76K Jun 30, 2026
CORO 0.00% 51 $ 19.051K Nov 16, 2026